2024-10-24 - Analysis Report
## Regeneron Pharmaceuticals Inc. (REGN) Stock Analysis

**Company Overview:** Regeneron Pharmaceuticals Inc. is a leading biotechnology company focused on the discovery, development, and commercialization of life-transforming medicines for serious diseases.

**Performance Analysis:**

**1)  Return and Relative Performance:**

* **REGN Cumulative Return:** 84.89%
* **S&P 500 (VOO) Cumulative Return:** 136.39%
* **Current Lag:** -51.5%
* **Relative Lag:** 26.27% 
    * **Interpretation:**  REGN has underperformed the S&P 500 over the period considered.  The current lag is within the middle of the historical range.

**2) Recent Price Action:**

* **Closing Price:** 968.03
* **5-Day Moving Average:** 986.68
* **20-Day Moving Average:** 1014.65
* **60-Day Moving Average:** 1100.32
    * **Interpretation:**  The stock is currently trading below its 5, 20, and 60-day moving averages, suggesting a downward trend.

**3) Technical Indicators:**

* **RSI:** 24.23  (Suggests the stock is oversold)
* **PPO:** -0.15 (Suggests a negative momentum)
* **Delta_Previous_Relative_Divergence:** -11.62 (Indicates a recent downward trend in the stock's relative performance)
* **Expected Return:** 0.0% (This means, based on current data, the stock is not expected to outperform the S&P 500 over the next 2 years)

**4) Recent Earnings and Outlook:**

| Date       | EPS    | Revenue  |
| ---------- | ------ | -------- |
| 2024-08-01 | 13.25  | 3.55 B$  |
| 2024-05-02 | 6.7    | 3.15 B$  |
| 2023-11-02 | 9.48   | 3.36 B$  |
| 2023-08-03 | 9.05   | 3.16 B$  |
| 2024-08-01 | 9.05   | 3.16 B$  | 

* **Interpretation:** The company has shown consistent revenue growth. However, recent EPS has declined. The latest earnings release showed a strong beat on both revenue and earnings. Analysts remain optimistic on REGN's long-term prospects. 

**5) News and Recent Events:**

* **Recent Market Outlook for REGN:**  Regeneron is currently facing challenges in its key business areas. However, the company has a robust pipeline and a strong financial position. 
* **Analyst Opinions:** Most analysts rate REGN as a "Buy" or "Strong Buy" with a 12-month price target of around $1,100.
* **Performance Highlights:** REGN's stock has been under pressure in recent months due to concerns about competition and the overall market sentiment. However, the company's fundamentals remain strong. 
* **News & Issues:**  Keep an eye on news related to Regeneronâ€™s key drugs (Eylea, Dupixent) like competition from other players in the market, FDA approvals for new drugs, and any regulatory updates. 

**6) Overall Analysis:**

* **Technicals:**  REGN is showing short-term weakness, but RSI indicates it's oversold, making a bounce possible. However, the PPO and moving averages indicate a larger downtrend.
* **Fundamentals:** Regeneron has a strong financial position and promising pipeline of new drugs. The recent earnings beat has rekindled investor confidence. 
* **Relative Performance:** The stock has lagged the market, but the current lag is within historical range. 

**7) Conclusion:**

REGN presents a mixed picture. While recent technical indicators suggest weakness, the fundamentals remain strong. The company's long-term growth potential and a recent positive earnings release could drive a rebound in the stock. However, the competitive landscape and market volatility require close monitoring. 

**Recommendation:**

* **Long-term investors:** If you believe in Regeneron's future, and its pipeline of new drugs, you could consider accumulating shares on dips.
* **Short-term traders:**  The recent technical weakness suggests caution. Wait for a clear sign of a rebound before considering any short-term trades.

**Disclaimer:** 
This is just an analysis based on the provided data and should not be considered financial advice.  Always consult with a qualified financial advisor before making any investment decisions. 
